[2]Kudo M, et al. IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study. Liver Cancer. 2022 Nov 28;12(3):238-250 .成 远 教授...
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025 Jan 18;405(10474):21...
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025 Jan 18;405(10474):21...
Now Viewing EP: 4.EMERALD-1 Study: Significance as Presented at ASCO GI 2024 EP: 5.EMERALD-1 Study: Outshining Negative Clinical Trials Based Upon TKI- and Liver-directed Therapies EP: 6.IMBrave-050 Study Overview EP: 7.Patient Profile 1: Advanced HCC Treated with Durvalumab and Tremelimumab...
[2]Kudo M, et al. IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study. Liver Cancer. 2022 Nov 28;12(3):238-250 . ...
Riccardo Lencioni, et al. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. 2024 ASCO GI, LBA 232. ...
Dr.Chan:I think the EMERALD-1 study brings several key messages.First of all,it’s a positive study,showing improvement in progression-free survival,time-to-progression,and response rates,all with a reasonable toxicity profile.These results support the use of this combination therapy in clinical ...
Dr. Chan: I think the EMERALD-1 study brings several key messages. First of all, it’s a positive study, showing improvement in progression-free survival, time-to-progression, and response rates, all with a reasonable toxicity profile. These results support the use of this combination therapy...
Analysis by Treatment Period and Liver Function in EMERALD-1: Phase 3 Study of Durvalumab (D) With/Without Bevacizumab (B) With Transarterial Chemoembolization (TACE) in Unresectable Hepatocellular Carcinoma (uHCC) Eligible for EmbolizationChan, Stephen L....
About the EMERALD-1 Study EMERALD-1 (MORF-057-201) is an open-label multi-center phase 2a trial designed to evaluate the efficacy, safety, and tolerability of MORF-057 in adults with moderate to severe ulcerative colitis....